The sentence in the ''Discussion'' describing the new pacemaker rate was incorrect. The correct version of the sentence is: The new pacemaker rate at 3 years of 31.4% is slightly higher than the 28% reported in the CoreValve US Pivotal High Risk Trial [8] , and considerably higher than that reported with balloon-expanding devices [9, 10] .
In the ''Limitations'', the sentence describing echocardiographic follow-up was incorrect. The correct sentence is: Echocardiographic compliance was 67%, as reported in the ''Results'' section.
The original article has been corrected. We apologize for any inconveniences caused.
The online version of the original article can be found under doi:10.1007/s00392-017-1120-3.
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